Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARGX-220
- Development stage
- Preclinical
- Lead developer
- argenx
- Modality
- Antibody-Based Therapeutics
01
Overview
ARGX-220 is a first-in-class experimental antibody therapy developed by argenx. It is described as a "sweeping antibody," but its precise molecular target and mechanism of action have not yet been publicly disclosed. The drug is part of argenx's Immunology Innovation Program, which focuses on developing novel therapies for immune-mediated diseases. As of early 2025, ARGX-220 remains in preclinical development, with investigational new drug (IND) applications planned to be filed by the end of 2025[2][4][7]. No clinical data or specific disease indications have been published.
Beyond the preview
Go deeper on ARGX-220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARGX-220.